Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.

Kato M, Chang CM.

CNS Drugs. 2013 May;27 Suppl 1:S11-9. doi: 10.1007/s40263-012-0029-7. Review.

PMID:
23709358
2.

Therapeutic potential of new second generation antipsychotics for major depressive disorder.

McElroy SL, Guerdjikova A, Mori N, Keck PE Jr.

Expert Opin Investig Drugs. 2010 Dec;19(12):1527-44. doi: 10.1517/13543784.2010.538048. Review.

PMID:
21105856
3.

Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.

Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, Pae CU.

Expert Rev Neurother. 2013 Jul;13(7):851-70. doi: 10.1586/14737175.2013.811901. Review.

PMID:
23898855
4.

Second-generation antipsychotics for major depressive disorder and dysthymia.

Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008121. doi: 10.1002/14651858.CD008121.pub2. Review.

PMID:
21154393
5.

Clinical issues in use of atypical antipsychotics for depressed patients.

Pae CU, Patkar AA.

CNS Drugs. 2013 May;27 Suppl 1:S39-45. doi: 10.1007/s40263-012-0032-z. Review.

PMID:
23709360
6.

Second-generation antipsychotics in major depressive disorder: update and clinical perspective.

Chen J, Gao K, Kemp DE.

Curr Opin Psychiatry. 2011 Jan;24(1):10-7. doi: 10.1097/YCO.0b013e3283413505. Review.

PMID:
21088586
7.

Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.

Lin CY, Tsai GE, Wang HS, Wu YH, Chiou CC, Wu VY, Lane HY.

J Clin Psychiatry. 2014 Sep;75(9):e924-31. doi: 10.4088/JCP.13m08843.

PMID:
25295435
8.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
9.

Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.

Kaneriya SH, Robbins-Welty GA, Smagula SF, Karp JF, Butters MA, Lenze EJ, Mulsant BH, Blumberger D, Anderson SJ, Dew MA, Lotrich F, Aizenstein HJ, Diniz BS, Reynolds CF 3rd.

JAMA Psychiatry. 2016 Apr;73(4):329-36. doi: 10.1001/jamapsychiatry.2015.3447.

10.
11.

[Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].

Erbe S, Gutwinski S, Bschor T.

Psychiatr Prax. 2012 Mar;39(2):57-63. doi: 10.1055/s-0031-1277013. Epub 2011 Dec 21. Review. German.

PMID:
22189902
12.

An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.

Trivedi MH, Thase ME, Osuntokun O, Henley DB, Case M, Watson SB, Campbell GM, Corya SA.

J Clin Psychiatry. 2009 Mar;70(3):387-96. Epub 2009 Mar 10.

PMID:
19284928
13.

Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.

Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G.

Ann Pharmacother. 2012 May;46(5):642-9. doi: 10.1345/aph.1Q326. Epub 2012 May 1.

PMID:
22550279
14.

Clinically relevant interactions between newer antidepressants and second-generation antipsychotics.

Spina E, de Leon J.

Expert Opin Drug Metab Toxicol. 2014 May;10(5):721-46. doi: 10.1517/17425255.2014.885504. Epub 2014 Feb 5. Review.

PMID:
24494611
15.

A systematic review of augmentation strategies for patients with major depressive disorder.

Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME.

Psychopharmacol Bull. 2009;42(3):57-90. Review.

PMID:
19752841
16.

Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.

Bauer M, Dell'osso L, Kasper S, Pitchot W, Dencker Vansvik E, Köhler J, Jørgensen L, Montgomery SA.

J Affect Disord. 2013 Oct;151(1):209-19. doi: 10.1016/j.jad.2013.05.079. Epub 2013 Jun 27.

PMID:
23810357
17.

Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression.

Chang CM, Sato S, Han C.

CNS Drugs. 2013 May;27 Suppl 1:S21-7. doi: 10.1007/s40263-012-0030-1. Review.

PMID:
23712796
18.

Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.

Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, Calabrese JR.

J Clin Psychiatry. 2011 Aug;72(8):1063-71. doi: 10.4088/JCP.09r05535gre. Epub 2010 Oct 19.

19.

Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.

Wright BM, Eiland EH 3rd, Lorenz R.

Pharmacotherapy. 2013 Mar;33(3):344-59. doi: 10.1002/phar.1204. Review.

PMID:
23456734
20.

Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.

Bobo WV, Shelton RC.

Expert Opin Pharmacother. 2009 Sep;10(13):2145-59. doi: 10.1517/14656560903130609. Review.

PMID:
19640209

Supplemental Content

Support Center